The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study

Table 2 Mean and standard deviations for outcome parameters with mean group differences and 95%CI for FACT-G, FACIT-F, TOI FACIT-F, and Total FACIT-F between cycles with fasting and regular diet of group A and B at day 8 after chemotherapy

Descriptives
Group	Cycle	N	Mean	Std. Deviation	95% Confidence Interval for Mean		Mean difference	Statistical significance
Group	Cycle	N	Mean	Std. Deviation	Lower Bound	Upper Bound	Mean difference	Statistical significance
FACT-G Group A	first half of a 4–6 cycle	52	71.1	18.7	65.9	76.3	9.2	0.041
FACT-G Group A	second half of a 4–6 cycle	27	61.9	18.5	54.6	69.2	9.2	0.041
FACT-G Group B	first half of a 4–6 cycle	46	76.0	17.2	70.9	81.1	2	0.576
FACT-G Group B	second half ofa 4–6 cycle	47	74.0	17.6	68.8	79.2	2	0.576
FACIT-F (FS) Group A	first half of a 4–6 cycle	52	33.9	13.4	30.2	37.6	9.1	0.006
FACIT-F (FS) Group A	second half of a 4–6 cycle	27	24.8	13.7	19.4	30.2	9.1	0.006
FACIT-F (FS) Group B	first half of a 4–6 cycle	46	33.4	14.0	29.3	37.6	1.8	0.521
FACIT-F (FS) Group B	second half of a 4–6 cycle	47	31.7	12.6	28.0	35.4	1.8	0.521
FACIT-F TOI Group A	first half of a 4–6 cycle	52	66	25	59	72.9	16.2	0.009
FACIT-F TOI Group A	second half of a 4–6 cycle	27	49.8	26.4	39.4	60.3	16.2	0.009
FACIT-F TOI Group B	first half of a 4–6 cycle	46	68.0	25.2	60.5	75.5	4.2	0.41
FACIT-F TOI Group B	second half of a 4–6 cycle	47	63.8	23.9	56.8	70.8	4.2	0.41
FACIT-F Total Group A	first half of a 4–6 cycle	52	105	30.4	96.6	113.5	18.3	0.013
FACIT-F Total Group A	second half of a 4–6 cycle	27	105	30.5	74.6	98.8	18.3	0.013
FACIT-F Total Group B	first half of a 4–6 cycle	46	109.5	29.8	100.6	118.3	4.2	0.531
FACIT-F Total Group B	second half of a 4–6 cycle	47	105.7	28.3	97.3	114.0	4.2	0.531

ISSN: 1471-2407